SCHEMBL19862425

SCHEMBL19862425

COc1cc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc(OC)c1C

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 14/20 0.72
▸ RXRA P19793 5/20 0.71
▸ CYP1A2 P05177 3/20 0.64
▸ MAPT P10636 3/20 0.64
▸ MAPK1 P28482 3/20 0.64
▸ PTGS2 P35354 2/20 0.64
▸ TDP1 Q9NUW8 2/20 0.64
▸ EGFR P00533 1/20 0.64
▸ ADORA3 P0DMS8 1/20 0.64
▸ DRD1 P21728 1/20 0.64
▸ PTGS1 P23219 1/20 0.64
▸ OPRM1 P35372 1/20 0.64
▸ PSEN1 P49768 1/20 0.64
▸ PSEN2 P49810 1/20 0.64
▸ APH1B Q8WW43 1/20 0.64
▸ NCSTN Q92542 1/20 0.64
▸ APH1A Q96BI3 1/20 0.64
▸ PSENEN Q9NZ42 1/20 0.64
▸ CYSLTR1 Q9Y271 1/20 0.64
▸ PTGDR2 Q9Y5Y4 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6938658 0.92 PPARG (0.71) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL17819199 0.92 PPARG (0.71) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL6936351 0.92 PPARG (0.71) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL17819202 0.92 PPARG (0.71) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL6936353 0.92 PPARG (0.71) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL8148383 0.91 PPARG (0.69) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL8148385 0.91 PPARG (0.69) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL8148388 0.91 PPARG (0.69) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL8149963 0.91 PPARG (0.69) PPARGRXRACYP1A2MAPTMAPK1
SCHEMBL24062036 0.89 PPARG (0.67) PPARGRXRACYP1A2MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180208573-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF BOYD, MICHAEL R. 2018-07-26 — — US disclosed
US-20180044314-A1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES ADT PHARMACEUTICALS INC (US) 2018-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208573-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF INSRR, INSR, BRCA1 PPARG 2746/4885RXRA 156/4885CYP1A2 265/4885
US-20180044314-A1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES KRAS, NRAS, HRAS PPARG 1654/4885RXRA 62/4885CYP1A2 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback